To Customers and Members of the Global Research Community:
Element Biosciences today issued the following statement in response to the complaint filed by 10x Genomics regarding Element’s AVITI24™ platform and related technologies. The complaint references U.S. Patent Nos. 11,021,737; 11,566,276; 11,566,277; and 12,264,358.
“Element strongly disagrees with the allegations made by 10x Genomics and believes the claims are without merit. We believe this lawsuit yet again reflects a broader pattern of using the same patent portfolio to stifle innovations across the industry. Element will vigorously defend its technology and remains focused on delivering differentiated solutions that expand scientific discovery and customer choice.”
Element was founded to expand innovation and competition in the life sciences industry. We remain confident in our technology, our intellectual property, and the differentiated value our products provide to customers.
We will continue to focus on supporting our customers and advancing the next generation of scientific innovation.
If you have any questions, please reach out to your Element contact.
Media Contact
media@elembio.com